Clinical Trial Update: Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction [Phase 3]

View source ↗

Summary

Phase 3 registrational study of omecamtiv mecarbil (AMG 423) for chronic heart failure with reduced ejection fraction has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• omecamtiv mecarbil (omecamtiv mecarbil)

Snippet

Sponsor: Cytokinetics | Conditions: Heart Failure | Phase 3 | Status: COMPLETED | Results posted: 2021-07-20